Faculty Opinions recommendation of Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

2014 ◽  
Author(s):  
Larry Bush
Keyword(s):  
Clostridium Difficile ◽  
Randomized Controlled Trials ◽  
Clostridium Difficile Infection ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

2014 ◽  
Vol 59 (3) ◽  
pp. 345-354 ◽  
Author(s):  
Stuart Johnson ◽  
Thomas J. Louie ◽  
Dale N. Gerding ◽  
Oliver A. Cornely ◽  
Scott Chasan-Taber ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Randomized Controlled Trials ◽  
Clostridium Difficile Infection ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

2012 ◽  
Vol 55 (suppl_2) ◽  
pp. S93-S103 ◽  
Author(s):  
Derrick W. Crook ◽  
A. Sarah Walker ◽  
Yin Kean ◽  
Karl Weiss ◽  
Oliver A. Cornely ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Randomized Controlled Trials ◽  
Clostridium Difficile Infection ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Is a Single Fecal Microbiota Transplant a Promising Treatment for Recurrent Clostridium difficile Infection?

2018 ◽  
Vol 5 (3) ◽  
Author(s):  
Susy S Hota ◽  
Susan M Poutanen
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Fecal Microbiota Transplantation ◽  
Clinical Effectiveness ◽  
Fecal Microbiota ◽  
Controlled Trials ◽  
Fecal Microbiota Transplant ◽  
Randomized Controlled ◽  
Recurrent Clostridium Difficile Infection ◽  
Promising Treatment

Abstract Clostridium difficile infection, a common hospital-associated infection, is a gastrointestinal illness that becomes recurrent in about 25% of infected patients. Fecal microbiota transplantation (FMT) is increasingly supported by clinical trials as an effective treatment for recurrent Clostridium difficile infection, but a number of questions remain about how it can be optimally performed. In this Perspective, we discuss controversies in FMT methodologies and reporting within randomized controlled trials, all of which may influence clinical outcomes in treated patients. Finally, we focus on the question of whether single vs multiple FMTs are necessary to achieve favorable outcomes for the treatment of recurrent Clostridium difficile infection, postulating on why there may be an association between number of FMTs and clinical effectiveness.

Sign in / Sign up

Export Citation Format

Share Document